AbbVie Inc.
ABBV
NYSE·Healthcare·Drug Manufacturers - General·Mkt cap $452.9B
$256.34
▼ -1.49%
P/E
72.22
Mkt Cap
$452.9B
52-Wk Range
$190.75–$267.47
52-Week Range
$190.75 - $267.47
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 22.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
6 reasons
- Blockbuster drug portfolio with HUMIRA, SKYRIZI, RINVOQ, and VENCLEXTA generating substantial recurring revenue
- Diversified therapeutic expertise across seven major disease areas reducing single-product risk
- Strong R&D capabilities and robust clinical pipeline for next-generation treatments
- Global manufacturing and distribution infrastructure enabling efficient market penetration
- Patent protection and exclusivity periods providing pricing power and market exclusivity
- Established relationships with healthcare providers, payers, and regulatory bodies
Bear Case
2 risks
- Low volatility (beta 0.3).
- Premium valuation to Large Cap Pharma peers
Growth
Stable outlook
Expansion of immunology and inflammation treatments in emerging markets
Value
Premium valuation to Large Cap Pharma peers
Momentum
Strong
+14.9% over 3m
Quality
Excellent
Excellent business quality
Dividend
Solid
2.66% yield
Smart-money signal
Who's buying ABBV right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 30, 2026
JUL 31, 2026
Reported EPS of $3.65 vs $3.61 consensus (+1.1% surprise). Revenue of $17.0B vs $16.8B expected (+1.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+1.1%
Revenue trend · last 8Q
—
+6%
+8%
+7%
+9%
+10%
+12%
+10%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$14.5B
$15.1B
$13.3B
$15.4B
$15.8B
$16.6B
$15.0B
$17.0B
Margins · last 8Q
Gross
84.7%
Operating
39.6%
Profit
21.3%
Wall Street consensus
13 analysts · 85% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
85%
Hold
15%
Sell
0%
Median Price Target
—
Latest: Piper Sandler · Aug 20, 2026
vs Industry
How ABBV stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related